Clearside Biomedical is a biopharmaceutical company focused on developing innovative drug therapies for blinding diseases of the eye, particularly those affecting the retina and choroid. The company's proprietary technology enables precise administration of medications to the back of the eye through suprachoroidal injection, utilizing the space between the choroid and sclera. This unique approach aims to redefine the treatment of retinal diseases by delivering drugs directly to the site of the condition.
Based in Alpharetta, United States, Clearside Biomedical has made significant strides in advancing ocular drug delivery. Their innovative suprachoroidal administration method leverages the eye's natural elasticity to distribute medication effectively, potentially improving treatment outcomes for patients with debilitating eye conditions. The company's work represents a notable contribution to the field of ophthalmology, offering new possibilities for addressing challenging retinal diseases.
